Do analysts prefer ACXP or CDT?

Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 2,008.84%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ACXP or CDT?

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$4.05 N/A CDT Equity N/A N/A -$39.22M -$14.27 thousand N/A

Is ACXP or CDT more profitable?

CDT Equity's return on equity of -145.29% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -153.92% -101.69% CDT Equity N/A -145.29% -103.25%

Does the media prefer ACXP or CDT?

In the previous week, CDT Equity had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Acurx Pharmaceuticals. CDT Equity's average media sentiment score of 0.56 beat Acurx Pharmaceuticals' score of 0.30 indicating that CDT Equity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CDT Equity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CDT or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CDT or PULM?

Pulmatrix has higher revenue and earnings than CDT Equity. Pulmatrix is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$14.27 thousand N/A Pulmatrix $7.81M 0.77 -$5.16M -$1.23 N/A

Is CDT or PULM more profitable?

Pulmatrix's return on equity of -107.84% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -145.29% -103.25% Pulmatrix N/A -107.84% -91.58%

Do analysts rate CURX or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CURX or CDT?

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$0.27 N/A CDT Equity N/A N/A -$39.22M -$14.27 thousand N/A

Is CURX or CDT more profitable?

Curanex Pharmaceuticals' return on equity of -85.41% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -85.41% -82.11% CDT Equity N/A -145.29% -103.25%

Do analysts prefer ENSC or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to ENSC or CDT?

In the previous week, CDT Equity had 3 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.59 beat CDT Equity's score of 0.56 indicating that Ensysce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CDT Equity 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CDT or PCSA?

Heatwurx has a consensus price target of $25.00, indicating a potential upside of 1,041.55%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than CDT Equity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, CDT or PCSA?

Heatwurx is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CDT Equity N/A N/A -$39.22M -$14.27 thousand N/A Heatwurx N/A N/A -$13.56M -$9.29 N/A

Is CDT or PCSA more profitable?

CDT Equity's return on equity of -145.29% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets CDT Equity N/A -145.29% -103.25% Heatwurx N/A -281.31% -200.80%

CDT Equity (CDT) Competitors

$3.59 +0.45 (+14.33%)

Closing price 08/5/2026 04:00 PM Eastern

Extended Trading

$3.48 -0.12 (-3.20%)

As of 08/5/2026 07:51 PM Eastern

Compare

CDT vs. ACXP, PULM, CURX, ENSC, and PCSA

Should you buy CDT Equity stock or one of its competitors? MarketBeat compares CDT Equity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CDT Equity include Acurx Pharmaceuticals (ACXP), Pulmatrix (PULM), Curanex Pharmaceuticals (CURX), Ensysce Biosciences (ENSC), and Heatwurx (PCSA). These companies are all part of the "pharmaceuticals" industry.

How does CDT Equity compare to Acurx Pharmaceuticals?

Acurx Pharmaceuticals (NASDAQ:ACXP) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$4.05	N/A
CDT Equity	N/A	N/A	-$39.22M	-$14.27 thousand	N/A

CDT Equity's return on equity of -145.29% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%
CDT Equity	N/A	-145.29%	-103.25%

Acurx Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 2,008.84%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acurx Pharmaceuticals has a beta of -2.03, indicating that its share price is 303% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

In the previous week, CDT Equity had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Acurx Pharmaceuticals. CDT Equity's average media sentiment score of 0.56 beat Acurx Pharmaceuticals' score of 0.30 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acurx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CDT Equity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of CDT Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Acurx Pharmaceuticals beats CDT Equity on 8 of the 13 factors compared between the two stocks.

How does CDT Equity compare to Pulmatrix?

CDT Equity (NASDAQ:CDT) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

CDT Equity has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, CDT Equity had 4 more articles in the media than Pulmatrix. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Pulmatrix. CDT Equity's average media sentiment score of 0.56 beat Pulmatrix's score of 0.00 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
Pulmatrix	Neutral

3.3% of CDT Equity shares are held by institutional investors. Comparatively, 11.8% of Pulmatrix shares are held by institutional investors. 10.8% of CDT Equity shares are held by company insiders. Comparatively, 0.6% of Pulmatrix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pulmatrix has higher revenue and earnings than CDT Equity. Pulmatrix is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$14.27 thousand	N/A
Pulmatrix	$7.81M	0.77	-$5.16M	-$1.23	N/A

Pulmatrix's return on equity of -107.84% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-145.29%	-103.25%
Pulmatrix	N/A	-107.84%	-91.58%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pulmatrix beats CDT Equity on 7 of the 11 factors compared between the two stocks.

How does CDT Equity compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals' return on equity of -85.41% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
CDT Equity	N/A	-145.29%	-103.25%

In the previous week, CDT Equity had 4 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Curanex Pharmaceuticals. CDT Equity's average media sentiment score of 0.56 beat Curanex Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
CDT Equity	Positive

Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
CDT Equity	N/A	N/A	-$39.22M	-$14.27 thousand	N/A

3.3% of CDT Equity shares are owned by institutional investors. 39.7% of Curanex Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Curanex Pharmaceuticals beats CDT Equity on 5 of the 9 factors compared between the two stocks.

How does CDT Equity compare to Ensysce Biosciences?

Ensysce Biosciences (NASDAQ:ENSC) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, CDT Equity had 3 more articles in the media than Ensysce Biosciences. MarketBeat recorded 4 mentions for CDT Equity and 1 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.59 beat CDT Equity's score of 0.56 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ensysce Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CDT Equity	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ensysce Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 3.3% of CDT Equity shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 10.8% of CDT Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ensysce Biosciences has higher revenue and earnings than CDT Equity. Ensysce Biosciences is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	1.10	-$10.18M	-$3.35	N/A
CDT Equity	N/A	N/A	-$39.22M	-$14.27 thousand	N/A

CDT Equity has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. CDT Equity's return on equity of -145.29% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
CDT Equity	N/A	-145.29%	-103.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

CDT Equity beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks.

How does CDT Equity compare to Heatwurx?

CDT Equity (NASDAQ:CDT) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

CDT Equity has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

In the previous week, CDT Equity had 4 more articles in the media than Heatwurx. MarketBeat recorded 4 mentions for CDT Equity and 0 mentions for Heatwurx. CDT Equity's average media sentiment score of 0.56 beat Heatwurx's score of 0.42 indicating that CDT Equity is being referred to more favorably in the media.

Company	Overall Sentiment
CDT Equity	Positive
Heatwurx	Neutral

Heatwurx is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CDT Equity	N/A	N/A	-$39.22M	-$14.27 thousand	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Heatwurx has a consensus price target of $25.00, indicating a potential upside of 1,041.55%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than CDT Equity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CDT Equity's return on equity of -145.29% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CDT Equity	N/A	-145.29%	-103.25%
Heatwurx	N/A	-281.31%	-200.80%

3.3% of CDT Equity shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 10.8% of CDT Equity shares are owned by insiders. Comparatively, 3.5% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

CDT Equity beats Heatwurx on 7 of the 13 factors compared between the two stocks.

Get CDT Equity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDT vs. The Competition

Export

Metric	CDT Equity	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.53M	$11.54B	$6.87B	$12.98B
Dividend Yield	N/A	2.74%	2.60%	9.79%
P/E Ratio	0.00	788.92	280.35	25.25
Price / Sales	N/A	749.63	604.25	94.30
Price / Cash	N/A	72.42	71.79	50.79
Price / Book	0.00	10.85	12.97	6.09
Net Income	-$39.22M	$2.82B	$3.49B	$347.95M
7 Day Performance	33.96%	2.41%	2.41%	3.11%
1 Month Performance	-20.98%	-1.74%	-2.87%	-2.99%
1 Year Performance	-99.90%	195.50%	75.29%	20.51%

CDT Equity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDT CDT Equity	0.2669 of 5 stars	$3.59 +14.3%	N/A	-99.9%	$1.53M	N/A	N/A	3	High Trading Volume
ACXP Acurx Pharmaceuticals	3.3925 of 5 stars	$1.43 flat	$31.00 +2,067.8%	-71.1%	$6.15M	N/A	N/A	3	Gap Up
PULM Pulmatrix	0.6684 of 5 stars	$1.66 -4.6%	N/A	-69.9%	$6.06M	$7.81M	N/A	20	Upcoming Earnings Gap Down
CURX Curanex Pharmaceuticals	0.8392 of 5 stars	$0.21 -1.0%	N/A	N/A	$5.96M	N/A	N/A	N/A	Gap Down
ENSC Ensysce Biosciences	0.7124 of 5 stars	$0.38 +37.2%	N/A	-83.8%	$5.91M	$5.07M	N/A	10	News Coverage Upcoming Earnings Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDT) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CDT Equity (CDT) Competitors

CDT vs. ACXP, PULM, CURX, ENSC, and PCSA

How does CDT Equity compare to Acurx Pharmaceuticals?

Summary

How does CDT Equity compare to Pulmatrix?

Summary

How does CDT Equity compare to Curanex Pharmaceuticals?

Summary

How does CDT Equity compare to Ensysce Biosciences?

Summary

How does CDT Equity compare to Heatwurx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CDT Equity (CDT) Competitors

CDT vs. ACXP, PULM, CURX, ENSC, and PCSA

How does CDT Equity compare to Acurx Pharmaceuticals?

Which has preferable earnings & valuation, ACXP or CDT?

Is ACXP or CDT more profitable?

Do analysts prefer ACXP or CDT?

Which has more risk and volatility, ACXP or CDT?

Does the media prefer ACXP or CDT?

Do insiders and institutionals believe in ACXP or CDT?

Summary

How does CDT Equity compare to Pulmatrix?

Which has more risk and volatility, CDT or PULM?

Does the media refer more to CDT or PULM?

Do insiders & institutionals hold more shares of CDT or PULM?

Which has better earnings and valuation, CDT or PULM?

Is CDT or PULM more profitable?

Do analysts recommend CDT or PULM?

Summary

How does CDT Equity compare to Curanex Pharmaceuticals?

Do analysts rate CURX or CDT?

Is CURX or CDT more profitable?

Does the media favor CURX or CDT?

Which has stronger earnings and valuation, CURX or CDT?

Do institutionals & insiders hold more shares of CURX or CDT?

Summary

How does CDT Equity compare to Ensysce Biosciences?

Does the media refer more to ENSC or CDT?

Which has more risk & volatility, ENSC or CDT?

Do institutionals & insiders hold more shares of ENSC or CDT?

Which has higher earnings and valuation, ENSC or CDT?

Is ENSC or CDT more profitable?

Do analysts prefer ENSC or CDT?

Summary

How does CDT Equity compare to Heatwurx?

Which has more risk & volatility, CDT or PCSA?

Does the media favor CDT or PCSA?

Which has stronger earnings & valuation, CDT or PCSA?

Do analysts recommend CDT or PCSA?

Is CDT or PCSA more profitable?

Do institutionals and insiders have more ownership in CDT or PCSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDT vs. The Competition

CDT Equity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools